During the past decade, CNE Prof. O.O. Shalimov Kharkiv City Clinical Hospital #2 of KCC conducted 54 clinical trials. In the 10-year time frame, 54 clinical trials started and 30 clinical trials were completed, i.e. on average, 55.6% percent of trials that started reached the finish line to date. In the past 5 years, 24 clinical trials started and 26 clinical trials were completed. i.e. 108.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CNE Prof. O.O. Shalimov Kharkiv City Clinical Hospital #2 of KCC" #1 sponsor was "Eli Lilly and Company" with 8 trials, followed by "Janssen Research & Development, LLC" with 8 trials sponsored, "Boehringer Ingelheim" with 6 trials sponsored, "Pfizer" with 5 trials sponsored and "Shire" with 5 trials sponsored. Other sponsors include 22 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CNE Prof. O.O. Shalimov Kharkiv City Clinical Hospital #2 of KCC" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 2 trials as a collaborator, "Dermira, Inc." with 2 trials as a collaborator, "Dr. Falk Pharma GmbH" with 1 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "CNE Prof. O.O. Shalimov Kharkiv City Clinical Hospital #2 of KCC" are "Ulcerative Colitis" (18 trials), "Crohn's Disease" (10 trials), "Crohn Disease" (7 trials), "Arthritis, Psoriatic" (4 trials) and "Colitis, Ulcerative" (4 trials). Many other conditions were trialed in "CNE Prof. O.O. Shalimov Kharkiv City Clinical Hospital #2 of KCC" in a lesser frequency.

Most popular intervention types in "CNE Prof. O.O. Shalimov Kharkiv City Clinical Hospital #2 of KCC" are "Drug" (56 trials), "Other" (9 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (33 trials), "Guselkumab" (6 trials), "Etrasimod" (4 trials), "Etrolizumab" (4 trials) and "Mirikizumab" (4 trials). Other intervention names were less common.

The vast majority of trials in "CNE Prof. O.O. Shalimov Kharkiv City Clinical Hospital #2 of KCC" are 59 trials for "All" genders.

Currently, there are NaN active trials in "CNE Prof. O.O. Shalimov Kharkiv City Clinical Hospital #2 of KCC". undefined are not yet recruiting, 12 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 27 completed trials in CNE Prof. O.O. Shalimov Kharkiv City Clinical Hospital #2 of KCC, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in CNE Prof. O.O. Shalimov Kharkiv City Clinical Hospital #2 of KCC, 0 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 48 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".